ALC ALCON INC IFRS
Ophthalmic Goods · NYSE · SEC CIK 1167379 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY4.9%
TTM net income YoY-3.7%
TTM EPS YoY-3.4%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR43.0%
Margins
Gross margin55.2%
Operating margin13.1%
Net margin9.4%
FCF margin16.6%
EBITDA margin—
Returns
ROE4.5%
ROA3.2%
ROIC (approx.)4.6%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets30.2%
Debt / equity0.21x
Current ratio2.12x
Interest coverage6.67x
Cash quality & payout
Operating cash flow / net income2.32x
Accruals ratio-4.2%
Payout ratio16.9%
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.40B | $9.91B |
| Cost of revenue | $4.59B | $4.33B |
| Gross profit | $5.75B | $5.51B |
| R&D expense | $990.00M | $876.00M |
| SG&A expense | $3.45B | $3.25B |
| Operating income | $1.36B | $1.41B |
| Interest expense | $204.00M | $192.00M |
| Pretax income | $1.16B | $1.26B |
| Income tax | $180.00M | $238.00M |
| Net income | $980.00M | $1.02B |
| EPS (basic) | 1.99 | 2.06 |
| EPS (diluted) | 1.98 | 2.05 |
| Weighted avg. shares (diluted) | 496.20M | 497.50M |
| Balance sheet | ||
| Cash & equivalents | $1.53B | $1.68B |
| Short-term investments | $80.00M | $153.00M |
| Receivables | $1.94B | $1.74B |
| Inventory | $2.39B | $2.27B |
| Current assets | $6.45B | $6.31B |
| PP&E, netmay include right-of-use assets (IFRS) | $4.77B | $4.39B |
| Goodwill | $9.26B | $8.95B |
| Intangibles | $9.01B | $8.59B |
| Total assets | $31.55B | $30.35B |
| Current liabilities | $3.05B | $2.28B |
| Short-term debt | $575.00M | $105.00M |
| Long-term debt | $4.16B | $4.54B |
| Total debt | $4.74B | $4.64B |
| Total liabilities | $9.52B | $8.79B |
| Shareholders' equity | $22.03B | $21.55B |
| Net debt | $3.21B | $2.97B |
| Cash flow statement | ||
| Operating cash flow | $2.27B | $2.08B |
| Capital expenditure | $543.00M | $473.00M |
| Free cash flow | $1.73B | $1.60B |
| Investing cash flow | -$1.34B | -$1.17B |
| Financing cash flow | -$1.12B | -$322.00M |
| Stock-based compensation | $171.00M | $162.00M |
| Dividends paid | $166.00M | $130.00M |
| Share buybacks | $676.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.